189 related articles for article (PubMed ID: 8819585)
41. Cross-resistance within the protease inhibitor class.
Race E
Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
[No Abstract] [Full Text] [Related]
42. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
43. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
[TBL] [Abstract][Full Text] [Related]
44. HIV-1 protease folding and the design of drugs which do not create resistance.
Broglia R; Levy Y; Tiana G
Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
[TBL] [Abstract][Full Text] [Related]
45. Quantitative structure-activity relationship studies on 1-aryl-tetrahydroisoquinoline analogs as active anti-HIV agents.
Chen KX; Xie HY; Li ZG; Gao JR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5381-6. PubMed ID: 18835162
[TBL] [Abstract][Full Text] [Related]
46. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study.
Pichová I; Weber J; Litera J; Konvalinka J; Vondrásek J; Soucek M; Strop P; Majer P; Heuser AM; Kraeusslich HG
Leukemia; 1997 Apr; 11 Suppl 3():120-2. PubMed ID: 9209317
[TBL] [Abstract][Full Text] [Related]
47. Predictors of virologic response to ritonavir-boosted protease inhibitors.
Marcelin AG; Flandre P; Peytavin G; Calvez V
AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
[TBL] [Abstract][Full Text] [Related]
48. HIV protease: enzyme function and drug resistance.
Gulnik S; Erickson JW; Xie D
Vitam Horm; 2000; 58():213-56. PubMed ID: 10668400
[TBL] [Abstract][Full Text] [Related]
49. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice.
Roberts NA; Craig JC; Sheldon J
AIDS; 1998 Mar; 12(5):453-60. PubMed ID: 9543442
[No Abstract] [Full Text] [Related]
50. Advances in non-peptidomimetic HIV protease inhibitors.
Pang X; Liu Z; Zhai G
Curr Med Chem; 2014 Jun; 21(17):1997-2011. PubMed ID: 24533811
[TBL] [Abstract][Full Text] [Related]
51. Inhibitors of HIV proteinase.
Martin JA; Redshaw S; Thomas GJ
Prog Med Chem; 1995; 32():239-87. PubMed ID: 8577919
[No Abstract] [Full Text] [Related]
52. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids.
Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K
Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594
[No Abstract] [Full Text] [Related]
53. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design.
McCarrick MA; Kollman P
Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189
[No Abstract] [Full Text] [Related]
54. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
Ghosh AK; Osswald HL; Prato G
J Med Chem; 2016 Jun; 59(11):5172-208. PubMed ID: 26799988
[TBL] [Abstract][Full Text] [Related]
55. Structure-based inhibitors of HIV-1 protease.
Wlodawer A; Erickson JW
Annu Rev Biochem; 1993; 62():543-85. PubMed ID: 8352596
[No Abstract] [Full Text] [Related]
56. Anti-HIV protease activity from rosa family plant extracts and rosamultin from Rosa rugosa.
Park JC; Kim SC; Choi MR; Song SH; Yoo EJ; Kim SH; Miyashiro H; Hattori M
J Med Food; 2005; 8(1):107-9. PubMed ID: 15857219
[TBL] [Abstract][Full Text] [Related]
57. [Anti-HIV drug development: future prospect and problems].
Baba M
Nihon Rinsho; 1993 Sep; 51 Suppl():357-63. PubMed ID: 7505851
[No Abstract] [Full Text] [Related]
58. Identification of the real molecular target for HIV inhibitors.
De Clercq E
Trends Pharmacol Sci; 2000 May; 21(5):167-8. PubMed ID: 10785647
[No Abstract] [Full Text] [Related]
59. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
Voshavar C
Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209
[TBL] [Abstract][Full Text] [Related]
60. HIV-1 protease: structure, dynamics, and inhibition.
Louis JM; Ishima R; Torchia DA; Weber IT
Adv Pharmacol; 2007; 55():261-98. PubMed ID: 17586318
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
